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ABSTRACT 
 
The specific binding of five reduced Schiff base derived 7-amino-coumarin compounds with 
antitumor activity to human serum albumin, the principal binding protein of blood, was 
studied by fluorescence spectroscopy. Their conditional binding constants were computed and 
the reversible binding at the Sudlow’s site I was found to be strong (KD ~ 0.03-2.09 M). 
Based on the data albumin can provide a depot for the compounds and is responsible for their 
biodistribution and transport processes. The experimental data is complemented by protein–
ligand docking calculations for two representatives which support the observations. The 
proton dissociation constants of the compounds were also determined by UV-Vis 
spectrophotometric and fluorometric titrations to obtain the actual charges and distribution of 
the species in the various protonation states at physiological pH.  
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1. Introduction 
Human serum albumin (HSA) is the main binding protein for many endogenous and 
exogenous substances in blood serum. The abundance of HSA in the circulatory system (0.63 
mM, 60% of the total serum protein level) and its extraordinary acceptor capability with a 
wide variety of molecules makes it an important tool in the development of novel therapeutic 
agents, as it influences their pharmacokinetic behavior [1,2]. Thus, HSA is able to increase 
the in vivo half-life and water solubility of drugs. The deeper knowledge of the binding ability 
of a drug to the non-specific transporter protein HSA becomes an important research field in 
chemistry, biochemistry and clinical medicine and screening of the binding to blood proteins 
is required by the FDA for a potential therapeutic agent [3-6]. 
 HSA is a globular protein, consists of a single chain with 585 amino acids organized 
in three similar domains (I, II, and III), each consisting of two subdomains (IA, IB, etc.). 
There are typical sites for binding of several substances such as amino acids, fatty acids, 
hormones. The principal regions of exogenous drug binding sites are located in hydrophobic 
pockets in subdomains IIA and IIIA (site I and site II, respectively) [7-10]. Furthermore, the 
enhanced permeability and retention effect of HSA in cancerous transformed tissues was 
reported in several studies [11]. Interaction with albumin is of great importance in respect of 
selective tumor targeting.  
 Coumarin and its derivatives of both natural and synthetic origins are well known 
compounds in the food and cosmetic industry, dye- and laser technology, as well as in 
medicine [12,13]. Coumarin compounds are oxygen-containing heterocycles with typical 
benzopyrone framework. In various pharmacological indications like antibiotic or 
anticoagulant therapy coumarin derivatives are well proven drugs [14,15]. Furthermore, they 
have attracted considerable interest as potential antifungal, analgesic, and vasodilator agents 
in recent years [16-18]. Coumarin derivatives have been also found to be selectively active 
against cancerous cell lines including malignant melanomas or renal cell carcinomas [19-22]. 
Halogen-substituted reduced Schiff base coumarin derivatives (1b, 1c, 1d) synthesized by 
Creaven et al. (Chart 1.) show remarkable anticancer activity against HT29 (human colon 
cancer) cell line (IC50 values: 60-82 M), which was found to be comparable to that of 
mitoxantrone, an antineoplastic chemotherapy drug [16]. Furthermore the dichloro compound 
1b shows additional activity against the MCF-7 (human breast cancer) cell line with an IC50 
value of 84 M [16].  
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HSA is a well-known transport vehicle of numerous coumarin derivatives [23-25]. 
Moreover their binding site is site I in most cases and warfarin as a coumarin derivative 
anticoagulant drug is also known to bind to the protein at this site [26].  
Among optical techniques, fluorescence spectroscopy is an appropriate method to 
determine the interaction between small ligand molecules and HSA. Coumarin derivatives 
exhibit strong fluorescence in the visible wavelength region which is usually significantly 
influenced by the surrounding medium [27]. At the same time HSA contains a single 
tryptophan (Trp 214) residue near to site I that is responsible for the majority of the intrinsic 
fluorescence of the protein. This emission can be quenched by a small molecule binding at or 
near the Trp214 as this amino acid unit is quite susceptible to changes in its environment. 
Thus the binding at the primarily proposed binding site can be studied directly.  
The purpose of the present study is to investigate the binding ability of some reduced 
Schiff-base coumarin derivatives to HSA using a fluorescence quenching technique, moreover 
for a deeper understanding of the mechanism of the interaction, proton dissociation (pKa) 
constants were determined for the compounds and the experimental data are complemented 
by protein–ligand docking calculations. 
Chart 1. 
  
 
2. Materials and methods 
2.1. Chemicals 
Reduced Shiff base derived coumarin compounds (1a, 1b, 1c, 1d, 1e) were synthesized as 
described previously [16]. HSA (as lyophilized powder with fatty acids), racemic warfarin, 
NaH2PO4, Na2HPO4 KOH, HCl and NaCl were obtained from Sigma-Aldrich in puriss 
quality. Doubly distilled Milli-Q water was used for sample preparations.  
HSA solution was freshly prepared before the experiments and its concentration was 
estimated from its UV absorption: 280 nm(HSA) = 36850 M
−1cm−1 [28]. Stock solutions of 
coumarin derivatives were prepared in dimethyl sulfoxide (DMSO) and were diluted with 
water or with water containing one equivalent of NaOH in case of albumin containing 
samples prior to the analyses.  
 
2.2. pH-dependent UV-Vis spectrophotometric and spectrofluorometric studies, lipophilicity 
predictions 
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The pH-dependent measurements for the determination of the proton dissociation constants of 
the compounds 1a, 1b, 1c, 1d, 1e were carried out at 25.0 ± 0.1 °C in aqueous phase at a 
constant ionic strength of 0.10 M (KCl) in the presence of ≤ 0.2% (v/v) DMSO content. The 
titrations were performed with HCl (0.10 M) and carbonate-free KOH solution (0.10 M) and 
their concentrations were determined by pH-potentiometric titrations. pH-Dependent titrations 
were performed in the pH range 2.0–11.5. The initial volume of the samples was 20.0 or 30.0 
mL. Samples were deoxygenated by bubbling purified argon through them for ca. 10 min 
prior the measurements. 
The proton dissociation constants and the spectra of the individual species in the 
various protonation states were calculated with the computer program PSEQUAD [29]. The 
calculations were always made from the experimental titration data measured in the absence 
of any precipitate in the solution. A Hewlett Packard 8452A diode array spectrophotometer 
was used to record the UV-Vis spectra in the interval 200–800 nm. The path length was 4 cm. 
The spectrophotometric titrations were performed on samples containing 0.5–2.0 M 
compounds.  
The pH-dependent fluorescence measurements were carried out on a Hitachi-4500 
spectrofluorometer with the appropriate excitation wavelength and emission wavelength 
ranges (see details in Table 1). The emission spectra were recorded in 1 cm quartz cell at 25.0 
± 0.1 °C using 5 nm/5 nm or 2.5 nm/ 2.5 nm slit widths. The samples contained 0.25–1.0 M 
compound. Three-dimensional spectra were recorded in the 200-450 nm excitation and 
210-600 nm emission wavelength regions at various pH values. 
ClogP values were calculated with the help of ACD/ChemSketch Freeware, version 
12.01 [30]. 
 
2.3. Interaction with HSA: Spectrofluorometric studies 
All samples were prepared in 20 mM phosphate buffer (pH 7.40). Samples contained 1 M 
HSA and various HSA-to-ligand ratios (from 1:0 to 1:10) were used. Spectra were recorded 
after 60 min incubations. The excitation wavelength was 295 nm, the emission intensities 
were read in the range of 305-550 nm with 5 nm/5 nm slit widths. The conditional binding 
constants were calculated with the computer program PSEQUAD [29].  
Corrections for self-absorbance and inner filter effect were necessary in the quenching 
experiments because fluorescence light was significantly absorbed by the coumarin-
derivatives. The corrections were carried out according to the Equation 1: 
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Fcorrected = Fmeasured × 10
(A(EX) + A(EM)) / 2  (1) [12] 
where Fcorrected and Fmeasured are the corrected and measured fluorescence intensities, and 
A(EX) and A(EM) are the absorbance values at the excitation and emission wavelengths of the 
samples, respectively. The inner filter effect in the case of pH-dependent titrations was 
negligible and therefore no corrections were applied. 
In the site marker displacement experiments, the HSA (1 M) to warfarin ratio was 
1:1 and the concentration of compound 1e was varied (0 – 3 M). Emission spectra were 
recorded after 1 h incubation at 310 nm excitation wavelength with 5 nm/10 nm slit widths. 
 
2.4. Molecular modeling studies 
The ligands were built using Maestro [31] and were subjected to a conformational search (CS) 
of 1000 steps, using a water environment model (generalized-Born/surface-area model) by 
means of Macromodel [32]. The algorithm used was based on the Monte Carlo method with 
the MMFFs force field and a distance-dependent dielectric constant of 1.0. The ligands were 
then energy minimized using the conjugated gradient method until a convergence value of 
0.05 kcal/(Å×mol) was reached, using the same force field and parameters used for the CS. 
Automated docking was carried out by means Autodock 4.0 [33]. The X-ray structure of HSA 
complexed with warfarin (2BXD PDB code [34]) was taken from the Protein Data Bank. The 
region of interest used by Autodock was defined in order to contain the residues within 10 Å 
from the original position of warfarin. The ligands were submitted to 30 genetic algorithm 
runs in the HSA site I and the best ranked pose was taken into account. All the molecular 
dynamics (MD) simulations were performed using AMBER11 [35] using the parm03 force 
field at 300 K. The complexes were placed in a rectangular parallelepiped water box. An 
explicit solvent model for water, TIP3P, was used, and the complexes were solvated with a 12 
Å water cap. Sodium ions were added as counter ions to neutralize the system. Prior to MD 
simulations, two steps of energy minimization were carried out. In the first stage, we kept the 
protein and ligand fixed with a position restraint of 100 kcal/(mol×Å2) and we just energy 
minimized the positions of the water molecules. In the second stage, we applied a restraint of 
10 kcal/(mol×Å2) only on the α carbons of the receptor. The two energy minimization stages 
consisted of 10000 steps. The first 1000 steps were Steepest Descent, and the last 9000 were 
Conjugate Gradient. Molecular dynamics trajectories were run using the energy minimized 
structure as the input, and particle mesh Ewald electrostatics [36] and periodic boundary 
conditions were used in the simulation. The time step of the simulations was 2.0 fs with a 
cutoff of 12 Å for the non-bonded interaction. SHAKE was employed to keep all bonds 
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involving hydrogen atoms rigid. Constant-volume periodic boundary MD was carried out for 
200 ps, during which the temperature was raised from 0 to 300 K. Then 4.8 ns of constant 
pressure periodic boundary MD was carried out at 300 K using the Langevin thermostat to 
maintain the temperature of our system constant. During the whole simulation, all the α 
carbons of the protein were blocked with a harmonic force constant of 10 kcal/(mol×Å2). 
General Amber force field (GAFF) parameters were assigned to the ligand, while partial 
charges were calculated using the AM1-BCC method as implemented in the Antechamber 
suite of AMBER 11. 
We extracted from the last 3 ns of MD of the ligand–receptor complexes, 300 
snapshots (at time intervals of 10 ps) for each species (complex, receptor and ligand). The 
various molecular mechanics–Poisson-Boltzmann solvent accessible surface area (MM-
PBSA) energy terms in Equation 2 were computed as follows. 
 
G = Gpolar + Gnonpolar + Emm - TS (2) 
 
Electrostatic, van der Waals and internal energies (Emm) were obtained using the SANDER 
module in AMBER 11. Polar energies (Gpolar) were obtained from the PBSA module of the 
AMBER 11 program (using the Poisson–Boltzman method) applying dielectric constants of 1 
and 80 to represent the gas and water phases, respectively. Nonpolar energies (Gnonpolar) 
were determined using the MOLSURF program. In order to compare the energetic 
interactions of the ligands into the protein, we took only the first three terms of Equation 2 
into account. 
 
3. Results and discussion 
3.1. Proton dissociation processes and calculated lipophilicity of the compounds 
The proton dissociation constants of the compounds 1a, 1b, 1c, 1d, 1e (Chart 1) possessing 
quite low water solubilities were determined by UV-Vis spectrophotometric as well by 
fluorometric titrations due to their high intrinsic fluorescence in aqueous solution in the 
presence of ≤ 0.2 % (v/v) DMSO. Results are collected in Table 1. 
Table 1 
The proton dissociation constants can be attributed most probably to the deprotonation 
of the hydroxyl functional group and the process is accompanied by characteristic changes of 
the ligand bands in the UV-Vis spectra. However, the development of strong bands with 
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higher lmax values which results in more extended conjugated  electron systems due to the 
deprotonation could be observed only for 1e (Fig. 1). On the other hand halogen disubstituted 
compounds display only a moderate shift in lmax, moreover in case of 1a the absorbance 
changes are minor in the higher wavelength region (Fig. S1 in Supplementary data). 
Fig. 1. 
Fig. 1b shows the increasing absorbance values for 1e at 410 nm and the concentration 
distribution curves calculated with the help of the pKa value as a function of pH. The 
difference between the calculated pKa values of compounds 1a, 1b, 1c, 1d, 1e is in good 
agreement with literature data considering the trend of their corresponding phenol analogues 
[37,38]. The halogen substitution in ortho and para positions to the hydroxyl group causes 
significantly lower pKa values compared to the unsubstituted derivative 1a owing to the 
negative inductive effect of the halogen atoms. Moreover the trend 1b > 1c > 1d in the pKa 
values can be explained by the decreasing electronegativity of the halogen resulting in a more 
increased electron delocalization in the aromatic ring, hence more stable conjugated bases can 
be formed. Nitro substitution in para position increases the acidity of hydroxyl group even 
more, as this moiety has a strong negative mesomeric effect. 
Spectrofluorometry was also applied to determine pKa of the compounds (Table 1). 
This technique is especially advantageous in the case of fluorescent compounds with poor 
water-solubility. In spite of the close structural similarities of the compounds their 
fluorescence behavior was quite different. The pH-dependent fluorescence emission spectra of 
1c are shown in Fig. 2 representing that the initial large intensity of the protonated form (HL) 
decreases ~38-fold as it transforms to its deprotonated (L-) form. During the deprotonation 
process no drift of the excitation and emission maxima could be observed. A similar behavior 
can be seen in case of 1a, where there are two excitation maxima with the same emission 
maximum (460 nm), one with lower intensity at 240 nm and the second with higher intensity 
at 360 nm. Representative 3-dimensional fluorescence spectra of 1a at pH 7.4 and 11.0 are 
shown in Fig. 3. On the other hand the deprotonation of 1b and 1d is not accompanied by 
such pronounced intensity decrease (see Fig. S2). Another interesting phenomenon is the 
unaffected fluorescence spectra of 1e between pH 3.3 and 11.0. It is well known that the 
electron donating groups (such as amino-group) substituted on coumarin into electron-
deficient positions (positions 4, 5 and 7) will increase the intramolecular electron transfer and 
thus enhance the fluorescence intensity of coumarin derivatives [12,27]. At the same time an 
electron-deficient 2-hydroxybenzyl substitution on the amino-group can decrease this effect. 
Accordingly further moderate decrease can be observed by substitution of electron 
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withdrawing-group(s) on the 2-hydroxybenzyl moiety. The pKa values calculated for 1a, 1c 
and 1d based on the fluorometric titrations are in good agreement with the results of UV-Vis 
measurements. In case of 1b the constant arisen from fluorometry is half order of magnitude 
higher than that obtained by UV-Vis, most probably some non-suspected excited state 
reactions can shift the acid-base equilibrium [12,39]. It is noteworthy that at pH < 3.0 (in case 
of 1c at pH < 5.0) all the studied compounds show significant changes in both UV-Vis and 
fluorescence emission spectra, which denote the deprotonation step of the amino group. 
However determination of pKa values was not feasible from the spectroscopic results. At the 
same time this process is of no significance, since it does not occur at physiological 
conditions. 
Fig. 2. 
Fig. 3. 
The presumed strongly lipophilic nature of the studied compounds did not allow us to 
determine the n-octanol/water partition coefficients (logP) by the traditional saturation shake 
flask method. Therefore, calculated lipophilicities (ClogP, Table 1) were predicted from the 
molecular structures using fragment based prediction with ACD/ChemSketch Freeware, 
version 12.01 [30]. Distribution coefficients (D7.4, Table 1) were calculated from the partition 
coefficients with the help of the proton dissociation constants at pH 7.4 [40]. Data reveal the 
more lipophilic character of the halogen disubstituted derivatives (1b, 1c, 1d), while the non-
substituted (1a) and nitro substituted (1e) compounds show diminished lipophilicity. 
 
3.2. Interaction with HSA: spectrofluorometric studies 
It is well known, that coumarin derivatives bind to HSA principally in the hydrophobic 
binding pocket site I [23-25], therefore first of all the interaction at this site was investigated 
in detail. HSA contains a single tryptophan (Trp214) residue that is responsible for the 
majority of the intrinsic fluorescence of the protein. Upon excitation at 295 nm, HSA emits 
strong fluorescence at 350 nm which can be attenuated by a binding event at, or close to, the 
Trp214 due to its susceptibility to changes in its environment. Addition of any ligand to HSA 
can quench its fluorescence via static quenching most probably with moderate to high 
efficiency, indicating that the conformation of the hydrophobic binding pocket in site I is 
significantly affected by the ligand binding. The time dependence of the interaction was 
studied and a rapid equilibration was found. After 20 minutes incubation no further changes in 
the fluorescence spectra could be observed (see Fig. S3), therefore a 1 hour incubation time 
was applied for the quenching experiments. Since the self-absorption of these compounds is 
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significant at the wavelength range of the quenching measurements, a correction equation was 
applied to minimize this effect (see Section 2.3). The conditional stability binding constants 
were calculated with the computer program PSEQUAD [29] using the spectra at the 
wavelength range where the overlapping of the emission of HSA and ligand was not 
significant. Compounds 1c, 1d and 1e show similar ability to bind on site I, the calculated 
binding constants are of considerable high value and are comparable with the binding constant 
of bilirubin to HSA (logK’ = 7.30 [41]). Moreover the binding constant calculated for 1a also 
exceeds the binding ability of warfarin to HSA (logK’ = 5.58 [42]), a drug which is known to 
be one of the most efficient binders to site I. The quenching ability of a number of the 
derivatives is summarized in Fig. 4. The simulated curves determined from the logK’ and 
“molar emission intensity” values (calculated with PSEQUAD [29], see details in 
Supplementary data) are in a fairly good agreement to those obtained by experimental data. 
Note that the saturation of the measurements does not tend to zero intensities; this 
phenomenon was included in the calculations. A possible explanation of this effect can be the 
partial quenching of Trp emission instead of complete quenching; moreover HSA contains 
other less emitting residues like Tyr whose emission is not affected by an interaction on site I. 
Fig. 4. 
As the pH-dependent studies demonstrated (vide supra) the protonated compounds display an 
outstanding fluorescence activity. This feature is preserved in physiological pH as well, hence 
according to literature data a significant change in the position and/or intensity of their 
fluorescence is expected upon binding to HSA [43]. However, the emission intensity of most 
of the compounds in our study was insensitive to binding to HSA. Only the fluorescence of 1c 
was altered in the course of interaction with HSA (see Fig. 5). Upon binding to HSA the 
emission maximum of 1c was shifted to shorter wavelength, but the predicted increase in its 
intensity did not occur and rather a moderate decrease could be observed. In this manner the 
observed behavior could not be explained by the general intramolecular charge transfer (ICT) 
vs. twisted intramolecular charge transfer (TICT) theory, where the ICT state denotes the 
highly fluorescent form and a fluorometric inactive form belongs to the TICT state. The TICT 
state results from a twisting of the electron donor amino-group around the N-C bond [44,45], 
that twisting can be restricted by interaction with HSA [43]. Most probably the relative 
position of the phenolic ring to the coumarin ring changes upon binding to HSA, which can 
cause an adverse change in the fluorescence intensity (see Section 3.3.). Besides, the 
compound 1c was sensitive likewise for the interaction with HSA. Fig. 5 shows a nonlinear 
increment in the intensity of emission of 1c at 450 nm. This phenomenon allowed us to 
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calculate binding constant logK’ = 7.54±0.06 from the side of the ligand in the wavelength 
range 400-500 nm, that is far consistent with the constant calculated from the quenching of 
Trp (see Table 1). This result confirms the assumption that the primary binding site is located 
in site I of HSA. 
 Additionally, displacement reactions with the anticoagulant drug warfarin, which is 
the mostly used and known site marker fluorescence probe for the binding site I of HSA [46], 
were carried out in the case of compound 1e, as a representative example. Warfarin has weak 
fluorescence intensity at its excitation wavelength maximum (310 nm), while binding to HSA 
induces a significant increase in the emission intensity (see Fig. S4).  As compound 1e does 
not emit at lEM < 390 nm the displacement of warfarin by 1e from this binding pocket of the 
protein is accompanied by a considerable decrease in the emission intensity as clearly shown 
in Fig. S4. 
 A further important observation is the significant increase in the solubility of the 
compounds in presence of HSA, most likely not exclusively as a result of the binding in site I, 
but a very fragile interaction on protein surface can ensure a 5-6-fold higher solubility [10].     
 Fig. 5. 
 
3.3. Molecular modeling 
In order to further understand and characterize the interaction of the studied compounds with 
HSA at site I, the compounds were analyzed by means of docking studies into the 
crystallographic structure of the protein. The ligands were docked into HSA using 
AUTODOCK 4.0 software [33], and the best pose was analyzed. Fig. 6a shows the 
interactions of the reference compound warfarin (2BXD PDB code [34]), with the coumarin 
moiety that interacts into the lipophilic pocket mainly delimited by L262, V265, L284, A285, 
I288, and T315 and the hydroxyl group that shows H-bond interactions with Y174 and H266. 
With regards to the phenyl ring it mainly interacts with K223, F235, W238 and A239 whereas 
the carbonyl oxygen interacts with R246. As shown in Fig. 6b, the docking of compound 1a 
suggests a completely different orientation for the coumarin moiety with the formation of 
hydrogen bonds with K223. The benzyl group occupies the lipophilic pocket mainly delimited 
by L262, V265, L284, A285, I288, and T315 that, as previously described, accommodates the 
coumarin moiety of warfarin and the 2-hydroxy oxygen forms an H-bond with R281. The 
docking of the anionic form of 1c highlights a disposition very similar to that observed for 
compound 1a, with the interaction of the coumarin moiety with K223, the interaction of the 
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aryl group into the lipophilic pocket and the phenolate oxygen that shows an ionic interaction 
with R281. 
Fig. 6. 
To confirm the reliability of the docking results, and to make a more precise analysis 
of the ligand-protein interaction, the HSA-1a and HSA-1c complexes were used as starting 
structures for 5 ns of MD simulation. Successively, the MD trajectories were further analyzed 
through the MM-PBSA method [47], which has shown to accurately estimate the ligand-
protein energy interaction [48-50]. This approach averages contributions of gas-phase 
energies, solvation free energies, and solute entropies calculated for snapshots of the complex 
molecule as well as the unbound components extracted from MD trajectories according to the 
procedure fully described in Section 2.4. 
As shown in Fig. S5, the complexes seem to be stable during the simulations. By 
analyzing the root-mean-square deviation (RMSD) of all the heavy atoms from the X-ray 
structures, we observed an initial increase due to the equilibration of the system, followed, 
after 1500 ps, by a stabilization of the RMSD value around 1.3 Å. Regarding the geometry of 
the compounds, we analyzed the RMSD of the position of the ligands with respect to the 
starting structures during the simulations. During the whole MD simulations, the ligands 
appeared to maintain a disposition similar to that of the starting structures, with an RMSD 
value between 0.6 and 0.9 Å. However, it is noteworthy that these calculations cannot give 
sufficient information about the conformational changes of the protein’s structure upon 
binding. 
With regards to the interactions of the two ligands 1a and 1c, they showed a 
disposition which is very similar to the starting docked structures, with the maintenance of the 
H-bond between the oxygen of the coumarin moiety and K223 and between the phenolic (1a) 
/ phenolate (1c) oxygen and R281 (see Fig. 7). 
Fig. 7. 
In order to further support the greater strength of the interaction of the phenolate oxygen with 
R281, to be able to explain the higher activity of compounds 1c, 1d, 1e, 1b; a quantitative 
evaluation of the interactions between HSA and 1a and 1c during the MD simulations have 
been carried out. In the Table 2, the MM-PBSA results calculated for each ligand into HSA 
are reported. 
 Table 2. 
The analysis of the MM-PBSA results highlighted that, with respect to compound 1a and due 
to a higher electrostatic interaction, compound 1c showed better interaction energy. 
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Furthermore, it is also interesting to note that, probably due to the presence of the two 
bromine atoms, the aryl moiety of 1c also showed slight higher lipophilic interaction energy. 
These findings strongly confirm the higher conditional binding constant determined for 1c 
compared with that of ligand 1a.   
 
4. Conclusions 
Recently more and more studies report the relevance of serum proteins in therapeutic 
strategies, since all of the systemic administered drugs are transported by the blood and its 
first encounter is not only with a number of low-molecular weight compounds and various 
cellular components, but also with a multitude of plasma proteins. The accumulation of HSA 
and HSA-bound drugs in solid tumors as a consequence of enhanced permeability and 
retention effect can be an operative way of selective tumor targeting. Coumarin derived 
compounds are used in a wide variety of industrial and medical applications. Lately promising 
coumarin compounds with various structures have shown potential as antitumor drugs. 
Hereby we examined some reduced Schiff base derived coumarin compounds with 
anticancer activity. Spectrofluorometry, UV-Vis photometry and molecular modeling 
calculations were performed to explore the interaction between HSA and these compounds 
with respect to the type and strength of interaction. pKa values were determined for the 
compounds in order to reveal the exact distribution of protonated and deprotonated forms at 
physiological pH. Compound 1a is almost exclusively in its protonated form, however 
halogen substituted derivatives 1b, 1c, 1d are about 50% deprotonated at pH 7.40. 1e owning 
the lowest pKa is deprotonated in 79%. Fluorescence quenching study with HSA showed a 
high to extraordinary high binding on site I for 1a and for the substituted compounds, 
respectively. The base compound 1a has somewhat higher, while the substituted derivatives 
have even higher binding affinity to site I compared with the well known coumarin derivative 
warfarin. Following the emission changes of compound 1c upon binding to HSA certified our 
assumption that the primary binding site of these compounds is located in site I of the protein. 
With help of molecular modeling study it was confirmed that these compounds most likely 
bind in site I in considerably different orientation than warfarin. Furthermore, molecular 
dynamic calculations pointed out the role of phenolate in development of electrostatic 
interactions between the small ligands and the protein.  
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Supplementary data 
Mathematical background of the calculation of the binding constants, figures for some pH-
dependent or time-dependence UV-Vis, fluorescence spectra, MD simulations. 
 
 
5. Abbreviations 
CS  conformational search 
D  distribution coefficient 
HSA  human serum albumin 
ICT  intramolecular charge transfer 
lEM  fluorescence emission wavelength  
lEX  fluorescence excitation wavelength 
MD  molecular dynamics 
MM-PBSA molecular mechanics–Poisson-Boltzmann solvent accessible surface area 
P  partition coefficient 
RMSD  root-mean-square deviation 
TICT  twisted intramolecular charge transfer 
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Table 1. 
Proton dissociation constants (pKa) of the reduced Schiff base coumarin derivatives determined 
by and UV-Vis spectrophotometry and spectrofluorometry; lEX)max, lEM)max (nm) and 
relative fluorescence emission intensity (a.u.) values for the protonated species (HL) determined 
by spectrofluorometric titrations; calculated distribution and partition coefficients; overall 
binding constants to HSA on site I (log K’){t = 25C} 
 1a 1b 1c 1d 1e 
pKa UV-Vis
a 9.63±0.02 7.51±0.01  7.46±0.01  7.36±0.02 6.80±0.01 
L-7.4 (%) 1 43 45 51 79 
HL7.4 (%) 99 57 55 49 21 
pKa Fluorometry
a 9.71±0.01 8.00±0.01 7.55±0.01 7.35±0.01 - 
l(EX)max 357 349 360 345 346 
FluHL
b 1.00 (453) 0.45 (443) 0.66 (449) 0.83 (445) 0.02 (443) 
ClogPc 2.9±0.4 4.4±0.4 4.9±0.5 5.1±0.5 3.0±0.4 
logD7.4
d 2.9 4.2 4.6 4.7 2.3 
logK’ (HSA)e 5.68±0.03 6.45±0.01 7.5±0.1 7.22±0.04 7.09±0.02 
KD
f 2.09 M 0.35 M 0.03 M 0.06 M 0.08 M 
a I = 0.1 M (KCl), values determined in aqueous phase in presence of  ≤0.2 % (v/v) DMSO.  
b Relative fluorescence intensities measured at excitation maxima (l(EX)max) 
c Predicted with ACD/ChemSketch Freeware, version 12.01 by fragment based method 
d D values were calculated at pH 7.4; D = P/(1+Ka/[H
+]) 
e Measured at pH 7.4 (20 mM phosphate buffer) in the presence of 1% (v/v) DMSO. 
f KD = dissociation constants of the HSA adducts. 
 
 
Table 2. MM-PBSA results for the 1a and 1c compounds. ΔPBSA is the sum of the 
electrostatic (Ele), van derWaals (VdW), polar (PB) and non-polar (PBSur) solvation free 
energy. Data are expressed as kcal×mol-1. 
 1a 1c 
VdW -36.4 -41.9 
Ele -31.3 -57.2 
PB 51.9 64.0 
PBsur -2.9 -3.1 
ΔPBSA -18.7±3.3 -38.1±3.0 
 
 
 18 
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1c Br Br
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Chart 1. Chemical formulae of the studied reduced Schiff base derivatives of coumarin  
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Fig. 1. pH-dependent UV–Vis-spectra of 1e (a), concentration distribution curves and 
measured absorbance values at 410 nm (□) as a function of pH for 1e (b) {c1e = 2 M; l = 4 
cm; t = 25 °C; I = 0.1 M (KCl)} 
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Fig. 2. pH-dependent fluorescence spectra of 1c; inset shows the concentration distribution 
curves and the pH-dependence of fluorescence at lEM = 450 nm {c1c = 0.5 M; lEX = 360 nm; 
5 nm/5 nm slits; l = 1 cm; t = 25 °C; I = 0.1 M (KCl)} 
 
 
 
 
 
(a)
 
(b)
 
 
Fig. 3. 3–Dimensional fluorescence spectra of 1a at pH 7.4 (a) and pH 11.0 (b) {c1a = 0.5 
M; 5 nm/5 nm slits; l = 1 cm; t = 25 °C; I = 0.1 M (KCl)} 
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Fig. 4. Measured and calculated quenching of the Trp fluorescence of HSA by the addition of 
1a (○, black dashed line), 1b (♦, grey solid line), 1c (▲, black solid line), or 1d (□, black 
dotted line) {cHSA = 1 M; lEX = 295 nm; lEM = 342 nm; 5 nm/5 nm slits; l = 1 cm; t = 25 
°C; pH = 7.4; 20 mM phosphate buffer} 
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Fig. 5. Fluorescence spectra of HSA-1c system, inset: intensity changes at 340 nm (black 
dots) and 450 nm (grey dots), grey dotted line shows the independent calibration for 1c {cHSA 
= 1 M; c1c = 0-4 M; lEX = 295 nm; 5 nm/5 nm slits; l = 1 cm; t = 25 °C; pH = 7.4, 20 mM 
phosphate buffer} 
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(b)(a) (c)
 
 
Fig. 6. Analysis of the interaction of warfarin (a) and docking of compound 1a (b) and 1c (c) 
into the HSA site I. 
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Fig. 7. Minimized average structures resulting from the MD simulation of the 1a-HSA (a) and 
1c-HSA (b) complexes. 
 
